Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Partner Fund Management and Aerie Pharmaceuticals Inc (AERI)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Partner Fund Management 0 2,210,020 0 6.2%
Partner Fund Management GP 0 2,210,020 0 6.2%
Partner Investment Management 0 32,071 0 0.1%
Partner Investment Management GP 0 32,071 0 0.1%
Brian D. Grossman 0 2,242,091 0 6.3%
Christopher M. James 0 2,242,091 0 6.3%
Christopher Medlock James
Christopher Medlock James
Partner Fund Management

Page 1 of 13 – SEC Filing



Washington, D.C. 20549



(Rule 13d-102)


Information Statement Pursuant to Rules
13d-1 and 13d-2

Under the Securities Exchange Act of

(Amendment No.      )*


Aerie Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)


(CUSIP Number)

July 5,

Date of Event Which Requires Filing of the

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Follow Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Trade (NASDAQ:AERI) Now!